SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001140361-24-048693
Filing Date
2024-12-06
Accepted
2024-12-06 17:09:33
Documents
3
Period of Report
2025-01-17

Document Format Files

Seq Description Document Type Size
1 PRE14A ny20039626x1_pre14a.htm PRE 14A 189114
2 ny20039626x1_pc01x1.jpg GRAPHIC 535116
3 ny20039626x1_pc02x1.jpg GRAPHIC 569940
  Complete submission text file 0001140361-24-048693.txt   1711502
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-40908 | Film No.: 241533155
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)